Overview

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

Status:
Recruiting
Trial end date:
2022-01-13
Target enrollment:
Participant gender:
Summary
This study is a phase 1 single dose escalation study of SHR-1905 in healthy subjects and subjects with mild asthma. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1905 in healthy subjects and subjects with mild asthma.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Hengrui Pharmaceutical Co., Ltd.